Johnson & Johnson (JNJ-1.00%) has many qualities. It is one of the largest healthcare companies in the world and boasts an ...

Medtronic is following a strategy that has worked well for Johnson & Johnson.

Johnson & Johnson (NYSE:JNJ) reported new clinical data for TECVAYLI plus DARZALEX FASPRO, CARVYKTI, and TREMFYA in multiple myeloma and axial psoriatic arthritis. Early line multiple myeloma data ...

Johnson & Johnson's oncology and immunology pipeline is firing on multiple cylinders, but a collapsing blockbuster drug and ...

A Los Angeles jury ordered Johnson & Johnson to pay $966 million to the family of a woman who died from mesothelioma, finding the company liable in the latest trial alleging its talc products cause ...

Johnson & Johnson has proposed a $5.5 billion settlement that would resolve roughly 76,000 lawsuits that claim that Johnson’s Baby Powder caused their ovarian cancer. (Photo Illustration by Justin ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Add Yahoo as a preferred source to see more of our stories on Google. On Sept. 29, 1982, Mary Kellerman woke up feeling sick. The 12-year-old girl from Elk Grove Village, a suburb of Chicago, asked ...

Monday - Friday, 6:00 - 7:00 PM ET CNBC's Jim Cramer on Thursday told investors why he thinks the stock of Johnson & Johnson is performing well this year even as the broader healthcare sector lags.

A Los Angeles jury awarded $40 million on Friday to two women who claimed that talcum powder made by Johnson & Johnson caused their ovarian cancer. The giant health care company said it would appeal ...

Today, Johnson & Johnson released its financial results for Q3 2025, which once again stunned Wall Street. So, sales of Rybrevant/Lazcluze, the 'diamond' in its oncology franchise, reached $198 ...

Monday - Friday, 6:00 - 7:00 PM ET As Wall Street navigates a jam-packed start to earnings season, CNBC's Jim Cramer explained what made shares of Johnson & Johnson rise after the company posted its ...